38341PAA0 Filings — Gossamer Bio, Inc. - FilingSpy
38341PAA0
Gossamer Bio, Inc.
Could not find a ticker for this position, may be a filing error
A clinical-stage biopharmaceutical company based in San Diego, Gossamer Bio develops treatments for rare diseases like pulmonary arterial hypertension (PAH), a progressive condition of high blood pressure in the lungs. Its lead drug candidate, seralutinib, is an inhaled dry-powder medicine designed to be breathed directly into the lungs. Founded in 2015, the company takes its name from the gossamer thread, meant to symbolize the fragile yet vital connections it builds with patients and partners.
Carter LauraChief Scientific Officer · 9 transactions
—
76.3Kas of Mar 2023
35.8K
6.9K
28.4K
Milligan SandraDirector · 2 transactions
—
58.0Kas of Aug 2025
—
58.0K
—
Dupont JakobChief Medical Officer · 5 transactions
—
46.5Kas of Feb 2020
88.5K
—
42.0K
Daniel Thomas ODirector · 1 transaction
—
38.1Kas of Feb 2019
—
—
—
Cox Russell J.Director · 1 transaction
—
7.2Kas of Feb 2019
—
7.2K
—
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +1.40M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.